ATE319714T1 - Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel - Google Patents

Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel

Info

Publication number
ATE319714T1
ATE319714T1 AT00969759T AT00969759T ATE319714T1 AT E319714 T1 ATE319714 T1 AT E319714T1 AT 00969759 T AT00969759 T AT 00969759T AT 00969759 T AT00969759 T AT 00969759T AT E319714 T1 ATE319714 T1 AT E319714T1
Authority
AT
Austria
Prior art keywords
alkyl
preparation
treatment
agents
cephalotaxins
Prior art date
Application number
AT00969759T
Other languages
German (de)
English (en)
Inventor
Jean-Pierre Robin
Robert Dhal
Freddy Drouye
Jean-Pierre Marie
Nina Radosevic
Julie Robin
Karine Souchaud
Patricia Bataille
Original Assignee
Stragen Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stragen Pharma Sa filed Critical Stragen Pharma Sa
Application granted granted Critical
Publication of ATE319714T1 publication Critical patent/ATE319714T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00969759T 2000-10-17 2000-10-17 Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel ATE319714T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/001593 WO2002032904A1 (en) 2000-10-17 2000-10-17 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents

Publications (1)

Publication Number Publication Date
ATE319714T1 true ATE319714T1 (de) 2006-03-15

Family

ID=11003995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969759T ATE319714T1 (de) 2000-10-17 2000-10-17 Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel

Country Status (12)

Country Link
US (1) US6579869B1 (https=)
EP (1) EP1328527B1 (https=)
JP (1) JP4837233B2 (https=)
CN (1) CN1303084C (https=)
AT (1) ATE319714T1 (https=)
AU (1) AU7940500A (https=)
CA (1) CA2426103A1 (https=)
DE (1) DE60026557T2 (https=)
DK (1) DK1328527T3 (https=)
ES (1) ES2258024T3 (https=)
PT (1) PT1328527E (https=)
WO (1) WO2002032904A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285546B2 (en) * 2000-10-17 2007-10-23 Stragen Pharma S.A. Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
US20040082565A1 (en) * 2002-07-17 2004-04-29 Chemgenex Therapeutics, Inc. Formulations and methods of administration of cephalotaxines including homoharringtonine
WO2004009030A2 (en) * 2002-07-22 2004-01-29 Chemgenex Pharmaceuticals Limited Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
US8466142B2 (en) 2008-03-03 2013-06-18 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
WO2010103405A2 (en) * 2009-03-11 2010-09-16 Jean-Pierre Robin Process for preparing cephalotaxine esters
CN102304132B (zh) * 2011-07-12 2015-01-28 南开大学 高效高立体选择性半合成三尖杉酯类生物碱的方法
CN103687859B (zh) * 2011-08-18 2016-08-17 杭州本生药业有限公司 高三尖杉酯碱的胺化衍生物、及其制备方法和应用
EP2746286A4 (en) * 2011-08-18 2015-01-07 Hangzhou Bensheng Pharmaceutical Co Ltd HOMOHARRINGTONIN AMINO DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
CN102675327B (zh) * 2012-03-01 2014-12-10 南开大学 三尖杉酯碱类似物及制备方法和应用
CN104293855A (zh) * 2014-10-15 2015-01-21 中国计量学院 脐孢木霉菌转化株在提高木霉素产量中的应用
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN106866690B (zh) * 2015-12-10 2019-10-11 南开大学 三尖杉酯类生物碱、其制备方法和用途
CN109111459B (zh) * 2017-06-22 2021-10-29 南华大学 含水杨酸三尖杉碱酯衍生物、制造方法及其用途
CN108378049A (zh) * 2018-05-02 2018-08-10 孙利嫚 一种含有粗榧生物碱和甲氧虫酰肼的农药组合物
WO2024061357A1 (zh) * 2022-09-22 2024-03-28 南开大学 三尖杉酯碱类衍生物及其药物组合物、制备方法和用途
KR20250160078A (ko) * 2024-05-03 2025-11-11 주식회사 아론티어 암 연관 섬유아세포 표적용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776292B1 (fr) * 1998-03-20 2004-09-10 Oncopharm Cephalotaxanes porteurs de chaine laterale et leur procede de synthese

Also Published As

Publication number Publication date
DK1328527T3 (da) 2006-07-17
DE60026557D1 (de) 2006-05-04
US6579869B1 (en) 2003-06-17
JP4837233B2 (ja) 2011-12-14
EP1328527B1 (en) 2006-03-08
PT1328527E (pt) 2006-06-30
EP1328527A1 (en) 2003-07-23
JP2004511560A (ja) 2004-04-15
WO2002032904A1 (en) 2002-04-25
CN1303084C (zh) 2007-03-07
CN1474821A (zh) 2004-02-11
DE60026557T2 (de) 2006-12-28
CA2426103A1 (en) 2002-04-25
AU7940500A (en) 2002-04-29
ES2258024T3 (es) 2006-08-16
HK1063183A1 (en) 2004-12-17

Similar Documents

Publication Publication Date Title
ATE319714T1 (de) Cephalotaxine, ihre herstellung und ihre verwendung in der behandlung von krebs, leukämie, parasiten einschliesslich derjenigen die gegen übliche chemotherapeutika resistent sind und als umkehrende mittel
MX9700557A (es) Dihidrobenzofuranos.
FR2359820A1 (fr) Antioxydants non migrateurs contenant un azide de sulfonyle
ATE359073T1 (de) Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel
TR200402262T4 (tr) Cilt için bronzlaşma maddesi
DE59708265D1 (de) Neue in 6-position substituierte phenanthridine
CA2077708A1 (en) Cyclic nitrones
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
ES2064729T3 (es) Complejos de rutenio (iii) como agentes antineoplasticos.
FI924118A0 (fi) Kinoxalinfoereningar och deras framstaellning och anvaendning.
AR024695A1 (es) Analogos de vitamina d3
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
FR2375234A1 (fr) 1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carboxylates et leur obtention
BR9708418A (pt) Amino-e trifenil-s-triazinas hodroxissubstituídas como estabilizadores
CY1106713T1 (el) Συνδυασμενη θεραπεια εναντιον καρκινωματων η οποια περιλαμβανει παραγωγα υποκαταστημενης ακρυλοϋλ δισταμυσινης και αλκυλιωτικους παραγοντες
ES8502189A1 (es) Procedimiento para preparar colorantes azoicos.
FR2369276A1 (fr) Nouve
FR2355500A1 (fr) Composition antimicrobienne a base de 1-acyloxy-2-imidazolyl-1-phenylethanes
ES2061841T3 (es) Barras de jabon sinteticas con propiedades mejoradas.
FR2446284A1 (fr) Tetrahydro-benzo(c)quinoleine-9(8h)ones
DE60006063D1 (de) Bis-terpyridinplatinkomplexe
ATE283837T1 (de) Neue 1,4-diamino-2-alkenyl-benzol-derivate und diese verbindungen enthaltende färbemittel
DK0390138T3 (da) Platinkomplekser og antitumormidler med indhold deraf som aktiv bestanddel
FR2369285A1 (fr) Agents de s
FR2378519A1 (https=)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328527

Country of ref document: EP

EEIH Change in the person of patent owner